Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Patent
1998-02-13
1999-11-09
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
424433, 424451, 424464, 514311, A61K 3147
Patent
active
059809140
ABSTRACT:
A new pharmaceutical composition is disclosed that comprises clioquinol, vitamin B.sub.12, and, optionally, pharmaceutical acceptable carriers and/or excipients. The use of the pharmaceutical composition removes or alleviates the side effects of clioquinol.
REFERENCES:
patent: 3574819 (1971-04-01), Gross et al.
patent: 5286492 (1994-02-01), Dettmar et al.
patent: 5373021 (1994-12-01), Marangos
patent: 5505958 (1996-04-01), Bello et al.
patent: 5607691 (1997-03-01), Hale et al.
patent: 5719138 (1998-02-01), Thomas, Jr. et al.
patent: 5776968 (1998-07-01), Berliner et al.
Price et al., Pathophysiology: Clinical Concepts of Disease Processes, 3rd ed., pp. 791-793, 1978.
Haensel et al, Therapeutic use of Chelate Formers and Metal Chelates, Pharm. Ztg. 118(26) 987-90, 1973.
"Idiosyncratic Neurotoxicity: Clioquinol and Bismuth," 1980, The Lancet pp. 857-858.
Baumgartner et al., 1979, Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan, Journal of Neurology, Nuerosurgery, and Psychiatry 42:1073-1083.
Beppu, H., 1973, "Toxicity of Clioquinol (5-chloro-7-iodo--8-hydroxy quinoline) on chick embryo dorsal root ganglia in tissue culture," 13:551-560 (w/ English abstract).
Borg-Neczak et al., 1994, "Effect of 8-Hydroxy-,8-Mercapto- and 5-Chlorol-7-iodo-8-hydroxy-quinoline on the Uptake and Distribution of Nickel in Mice," Pharmacology & Toxicology 74:185-192.
Bush et al., 1994, "Rapid Induction of Alzheimer A.beta. Amyloid Formation by Zinc," Science 265:1464-1467.
Bush et al., 1995, "The Role of Zinc in the Cerebral Deposition of A.beta. Amyloid in Alzheimer's Disease," Amyloidogenesis pp. 607-618.
Bush et al., 1995, "Zinc and Alzheimer's Disease," Science 268:1921-1923.
Chaiyabutr et al., 1985, "Urinary Bladder Effects After Oral Dosages of the ntidiarrhoeal Drug (Clioquinol/Phanquinone/Oxyphenonium Bromide) in Experimental Drugs," J. Med. Ass. Thailand 68(12):649-653.
Committee on Drugs, "Blindness and Neuropathy From Diiodohydroxyquin-Like Drugs," American Academy of Pediatrics, pp. 378-379.
Crapper McLachlan et al., 1991, Intramuscular desferrioxamine in patients with Alzheimer's disease, The Lancet 337:1304-1308.
Degen et al., 1979, "Percutaneous Absorption of Clioquinol (Vioform.RTM.)," Dermatologica 159:295-301.
Esler et al., 1996, "Zinc-Induced Aggregation of Human and Rat .beta.-Amyloid Peptides in Vitro," Jounral of Neurochemistry 66(2):723-732.
Fitzgerald, 1995, "Zinc and Alhzeimer's Disease," Science 268:1920-1923.
Goto et al., 1982, "Impairment of Visual System of Beagles Orally Ingesting Clioquinol," The Journal of Toxicological Sciences 7:19-25.
Goto et al., 1982, "Deterioration of Spinal Reflex in Beagles Orally Ingesting Clioquinol," The Journal of Toxicological Sciences 7:-12.
Holtzman et al., 1996, "Developmental abnormalities and age-related neurodegeneration in a mouse model on Down syndrome," Proc. Natl. Acad. Sci. USA 93:13333-13338.
Hori et al., 1987, "5-Chloro-7-Iodo-8-Hydroxyquinoline (Clioquinol) Inhibits The Nerve Growth Factor-Induced Stimulation Of RNA Synthesis In Neonatal Rat Superior Cervical Ganglion, In Vitro," The Journal of Toxicological Sciences 12:97-109.
Jack et al., 1973, "Pharmacokinetics of Iodochlorhydroxyquin in Man," Journal of Pharmaceutical Sciences 62(12):1929-1932.
Kaiser, 1994, "Alzheimer's: Could Thre Be a Zinc Link?," Science 265:1365.
Kawahara et al., 1997, "Alzheimer's Disease Amyloid .beta.-Protein Forms Zn.sup.2+ -Sensitive, Cation-Selective Channels Across Excised Membrane Patches from Hypothalamic Neurons," Biophysical Journal 73:67-75.
Kirschner et al., 1987, "Synthetic peptide homologous to .beta. protein from Alzheimer disease forms amyloid-like fibrils in vitro," Proc. Natl. Acad. Sci. USA 84:6953-6957.
Kono, R., 1975, "Introductory Review Of Subacute Myelo-Optico-Neuropathy (SMON) And Its Studies Done By The SMON Research Commission," Japan J. Med. Sci. Biol. 28:1-21.
Kotaki et al., 1983, "Intestinal Absorption and Metagolism of Clioquinol in the Rat," J. Pharm. Dyn. 6:881-887.
Koyama ete al., 1989, "Electrophysiological changes in the fasciculus gracilus of the cat following chronic clioquinol administration," Journal of the Neurological Sciences 94:271-282.
LaFerla et al., 1996, "Extracellular Deposition of .beta.-Amyloid upon p53-dependent Neuronal Cell Death in Transgenic Mice," J. Clin. Invest. 98(7):1626-1632.
Meade, T.W., 1975, "Subacute myelo-optic neuropathy and clioquinol," Brit. J. prev. soc. Med. 29:157-169.
Mumenthaler et al., 1979, "Transient global amnesia after clioquinol," Journal of Neurology, Neurosurgery, and Psychiatry 42:1084-1090.
Muratov et al., 1983, "Interaction of Voltaren and some Pyrazolone and Aniline Derivatives with Endoperoxide Prostaglandin Synthetase," pp. 44-46 (w/ English abstract).
Nakae et al., 1972, "Relation between Subacute Myelooptic Neuropathy (S.M.O.N.) and Clioquinol: Nationwide Survey," The Lancet pp. 171-173.
Oakley, Jr., G.P., 1973, "The Neurotoxicity of the Halogenated Hydroxyquinolines," JAMA 225(4):395-397.
Oguro, 1974, "The interference of the water-soluble organic compounds in atomic absorption spectrophotometry of calcium," Japan Analyst pp. 1375-1378.
Okada et al., 1984, "Effects Of Metal-Containing Drugs Taken Simultaneously With Clioquinol Upon Clinical Features Of SMON," The Journal of Toxicological Sciences 9:327-341.
O'Mahony et al., 1995, "Bone Aluminium Content in Alzheimer's Disease," Dementia 6:69-72.
Ozawa et al., 1986, "Experimental Clioquinol Intoxication in Rats: Abnormalities in Optic Nerves and Small Nerve Cells of Dorsal Root Ganglia," Acta Neuropathol (Berl) 69:272-277.
Pericin, 1979, "Comparison of the Acute Toxicity of Clioquinol, Histamine, and Chloroform in Different Strains of Mice," Arch. Toxicol. Supple. 2:371-373.
Polites, 1996, "Transgenic model applications to drug discovery," Int. J. Exp. Path. 77:257-262.
Ricoy et al., 1982, "Subacute Myelo-Optic Neuropathy (SMON)," Journal of the Neurological Sciences 53:241-251.
Ross et al., 1997, "Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins," Nature Medicine 3(8):872-878.
Sargeaunt et al., 1976, "In vitro sensitivity of Entamoeba histolytica to furazolidone and iodochlohydroxyquin, separate and combined," Transactions of the Royal Society of Tropical Medicine and Hygiene 70(4):54-56.
Schmid et al., 1973, "Studies of the Distribution and Excretion of Clioquinol in the Animal," Arzneim.-Forsch. (Drug Res.) 23(11):1560-1566.
Shigematsu, I., 1975, "Subacute Myelo-Optico-Neuropathy (SMON) And Clioquinol," pp. 35-54.
Shiraki, H., 1972, "The Neuropathology Of Subacute Myelo-Optico-Neuropathy, "SMON", In The Humans," pp. 101-164.
Sobue et al., 1971, "Myeloneuropathy with abdominal disorders in Japan," Neurology 21:168-173.
Sobue, "Clinical aspects of subacute myelo-optico-neuropathy (SMON)," Handbook of Clinical Neurology 37:116-139.
Tamura et al., 1973, "Identification Of Green Pigment And Analysis Of Clioquinol In Specimens From Patients With Subacute Myelo-Optico-Neuropathy," Clinica Chimica Acta 47:13-20.
Tamura, Z., 1975, "Clinical Chemistry of Clioquinol," pp. 69-77.
Tateishi et al., 1975, "Experimental Reproduction of SMON in Animals by Prolonged Administration of Clioquinol: Clinoco-Pathological Finding," 28:165-186.
Tateishi et al., 1976, "Neurotoxicity of Iodoxyquinoline: A Further Study on Beagle Dogs," 28:187-195.
Thomas et al., 1984, "Correlated Nerve Conduction, Somatosensory Evoked Potential And Neuropathological Studies In Clioquinol And 2,5-Hexanedione Neurotoxicity In The Baboon," Journal of the Neurological Sciences 64:277-295.
Tsubaki et al., 1971, "Neurological Syndrome Associated with Clioquinol," The Lancet 696-697.
Wadia, 1984, "SMON as seen from Bombay," Acta Neurol Scand 70(suppl 100):159-164.
Weathersbee, A.A., 1943, "Observations On The Relative Attractiveness Of Man And Horse For Anopheles Albimanus Weideman," The American Journal of Tropical Medicine 14:25-33.
Weismann et al., 1978, "Effects of Penicillamine and Hydroxyquinoline on Absorption of Orally Ingested .sup.65 Zinc
P.N. Gerolymatos S.A.
Page Thurman K.
Seidleck Brian K.
LandOfFree
Clioquinol for the treatment of Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clioquinol for the treatment of Parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clioquinol for the treatment of Parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1452070